Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
View/ Open
Date
2022-03-04ICR Author
Author
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Iglesias Docampo, LC
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Jayaprakash, V
Wei, L
Ferris, RL
Type
Journal Article
Metadata
Show full item recordAbstract
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
clinical trial
squamous cell carcinoma of head and neck
nivolumab
immunotherapy
SQUAMOUS-CELL CARCINOMA
INVESTIGATORS CHOICE
OPEN-LABEL
CETUXIMAB
CHEMOTHERAPY
PLATINUM
Research team
Targeted Therapy
Language
eng
Date accepted
2021-11-30
License start date
2022-03-04
Citation
ONCOLOGIST, 2022, 27 (2), pp. E194 - E198 (5)
Publisher
OXFORD UNIV PRESS